Coversyl: Effective Blood Pressure Control for Cardiovascular Health
Coversyl
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.60 | $48.00 (0%) | 🛒 Add to cart |
| 60 | $1.40 | $96.00 $84.00 (12%) | 🛒 Add to cart |
| 90 | $1.20 | $144.00 $108.00 (25%) | 🛒 Add to cart |
| 120 | $1.15 | $192.00 $138.00 (28%) | 🛒 Add to cart |
| 180 | $1.10 | $288.00 $198.00 (31%) | 🛒 Add to cart |
| 270 | $0.90 | $432.00 $243.00 (44%) | 🛒 Add to cart |
| 360 | $0.80
Best per pill | $576.00 $288.00 (50%) | 🛒 Add to cart |
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.00 | $40.00 (0%) | 🛒 Add to cart |
| 30 | $1.70 | $60.00 $51.00 (15%) | 🛒 Add to cart |
| 60 | $1.50 | $120.00 $90.00 (25%) | 🛒 Add to cart |
| 90 | $1.33 | $180.00 $120.00 (33%) | 🛒 Add to cart |
| 120 | $1.20 | $240.00 $144.00 (40%) | 🛒 Add to cart |
| 180 | $1.15 | $360.00 $207.00 (42%) | 🛒 Add to cart |
| 270 | $1.10 | $540.00 $297.00 (45%) | 🛒 Add to cart |
| 360 | $1.00
Best per pill | $720.00 $360.00 (50%) | 🛒 Add to cart |
| Product dosage: 8mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $3.00 | $60.00 (0%) | 🛒 Add to cart |
| 30 | $2.80 | $90.00 $84.00 (7%) | 🛒 Add to cart |
| 60 | $2.60 | $180.00 $156.00 (13%) | 🛒 Add to cart |
| 90 | $2.40 | $270.00 $216.00 (20%) | 🛒 Add to cart |
| 120 | $2.20 | $360.00 $264.00 (27%) | 🛒 Add to cart |
| 180 | $2.00 | $540.00 $360.00 (33%) | 🛒 Add to cart |
| 270 | $1.70 | $810.00 $459.00 (43%) | 🛒 Add to cart |
| 360 | $1.50
Best per pill | $1080.00 $540.00 (50%) | 🛒 Add to cart |
Coversyl (perindopril) is an angiotensin-converting enzyme (ACE) inhibitor prescribed for the management of hypertension and heart failure, as well as for the secondary prevention of cardiovascular events in patients with stable coronary artery disease. As a prodrug, perindopril is metabolized to its active form, perindoprilat, which exerts its therapeutic effect by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This action results in decreased vascular resistance, lowered blood pressure, and reduced cardiac workload, offering a well-established option within evidence-based treatment protocols for long-term cardiovascular risk reduction.
Features
- Active ingredient: Perindopril (as perindopril arginine or perindopril erbumine)
- Pharmacological class: Angiotensin-converting enzyme (ACE) inhibitor
- Available formulations: Oral tablets (2 mg, 4 mg, 8 mg strengths)
- Administration: Once-daily dosing
- Prescription status: Requires medical prescription
- Mechanism: Inhibition of angiotensin-converting enzyme, reducing angiotensin II formation
Benefits
- Provides consistent 24-hour blood pressure control with single daily dosing, supporting adherence to treatment regimens.
- Reduces the risk of major cardiovascular events, including myocardial infarction and stroke, in high-risk patient populations.
- Demonstrates cardioprotective effects by decreasing left ventricular hypertrophy and improving endothelial function.
- Offers a favorable safety and tolerability profile for long-term use in chronic management of hypertension and heart failure.
- May provide renal protective benefits in hypertensive patients with diabetes by reducing proteinuria.
- Can be used effectively as monotherapy or in combination with other antihypertensive agents, such as diuretics or calcium channel blockers.
Common use
Coversyl is primarily indicated for the first-line treatment of essential hypertension. It is also approved for use in the management of stable coronary artery disease to reduce the risk of cardiovascular events in patients who have previously experienced myocardial infarction or revascularization procedures. Additionally, it is utilized as part of a comprehensive treatment regimen for chronic heart failure, typically in combination with other heart failure medications. The medication may be prescribed off-label for certain renal conditions characterized by proteinuria, particularly in diabetic nephropathy, where ACE inhibition has demonstrated protective effects on renal function.
Dosage and direction
The recommended initial dosage for hypertension is 4 mg once daily, which may be increased to 8 mg once daily after at least one month of treatment based on therapeutic response and tolerability. For elderly patients or those with renal impairment, a starting dose of 2 mg once daily is recommended, with careful titration. In heart failure, treatment should be initiated under close medical supervision at 2 mg once daily, with gradual increases to a maintenance dose of 4 mg once daily. Tablets should be taken orally, preferably at the same time each day, with or without food. Consistency in administration timing helps maintain stable plasma concentrations. Dosage adjustments should be made based on regular blood pressure monitoring, renal function assessment, and clinical response.
Precautions
Before initiating Coversyl therapy, assess renal function and electrolytes, as ACE inhibitors can cause increased serum creatinine and potassium levels. Monitor blood pressure regularly, especially after initiation or dose adjustment. Use with caution in patients with renal artery stenosis, as ACE inhibitors may cause reversible increases in blood urea nitrogen and serum creatinine. Exercise particular caution in patients with collagen vascular diseases or those receiving immunosuppressive therapy, due to increased risk of neutropenia/agranulocytosis. Avoid use in pregnancy, as ACE inhibitors can cause injury and death to the developing fetus. Patients should be advised to report any signs of infection (e.g., fever, sore throat) as these may indicate neutropenia. Caution is advised in patients undergoing major surgery or anesthesia.
Contraindications
Coversyl is contraindicated in patients with a history of hypersensitivity to perindopril or any other ACE inhibitor. It is contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy. Do not use in patients with hereditary or idiopathic angioedema. Concomitant use with aliskiren-containing products is contraindicated in patients with diabetes. Avoid use during pregnancy, particularly in the second and third trimesters. Contraindicated in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney.
Possible side effects
Common side effects (≥1%) include: persistent dry cough, dizziness, headache, fatigue, and gastrointestinal disturbances such as nausea, vomiting, or diarrhea. Less frequently (0.1-1%), patients may experience orthostatic hypotension, rash, taste disturbance, or muscle cramps. Rare but serious adverse effects (<0.1%) include angioedema (which may involve swelling of the face, lips, tongue, or larynx), neutropenia/agranulocytosis, hepatic dysfunction, and severe hypotension. Renal impairment may occur, particularly in volume-depleted patients or those with pre-existing renal disease. Hyperkalemia may develop, especially in patients with renal impairment or diabetes, or those taking potassium-sparing diuretics or potassium supplements.
Drug interaction
Coversyl may interact with several medication classes. Concomitant use with diuretics may potentiate hypotensive effects. NSAIDs may reduce the antihypertensive effect and increase the risk of renal impairment. Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase the risk of hyperkalemia. Lithium levels may increase with ACE inhibitor coadministration, requiring monitoring. Enhanced hypotensive effects may occur with other antihypertensive agents. Dual blockade of the renin-angiotensin system with ARBs, aliskiren, or other ACE inhibitors increases risks of hypotension, hyperkalemia, and renal impairment. Allopurinol and immunosuppressants may increase the risk of hypersensitivity reactions.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistent daily administration is important for maintaining stable blood pressure control. Patients should be advised to establish a routine for medication administration, such as taking it with another daily activity, to minimize the likelihood of missed doses.
Overdose
Symptoms of overdose may include pronounced hypotension, which could manifest as dizziness, lightheadedness, or syncope. Bradycardia, circulatory shock, electrolyte disturbances, and renal failure may occur. In case of suspected overdose, immediately discontinue the medication and place the patient in a supine position with elevated legs. Treatment is primarily supportive and symptomatic, including intravenous fluids for volume expansion. Angiotensin II infusion or catecholamines may be considered for severe hypotension unresponsive to volume expansion. Hemodialysis may remove perindoprilat, particularly in patients with renal impairment. Close monitoring of vital signs, electrolyte balance, and renal function is essential.
Storage
Store at room temperature (15-30°C or 59-86°F) in the original container to protect from moisture and light. Keep the bottle tightly closed when not in use. Do not store in bathrooms or other areas with high humidity. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly discard any unused medication that is no longer needed or has expired. Do not flush medications down the toilet or pour them into a drain unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses to medication may vary. The prescribing physician should be consulted for specific medical advice, diagnosis, and treatment recommendations. Never disregard professional medical advice or delay seeking it because of something you have read in this product information. Healthcare professionals should reference the full prescribing information before initiating therapy. Patients should not make any changes to their medication regimen without consulting their healthcare provider.
Reviews
Clinical trials and post-marketing surveillance have demonstrated Coversyl’s efficacy in blood pressure control and cardiovascular risk reduction. The EUROPA study, a landmark trial involving over 12,000 patients with stable coronary artery disease, showed that perindopril significantly reduced the relative risk of cardiovascular death, myocardial infarction, or cardiac arrest by 20% compared to placebo. In hypertension management, perindopril has shown consistent 24-hour blood pressure control with smooth reduction without excessive peak effects. Many clinicians appreciate its once-daily dosing regimen, which supports patient adherence. The dry cough associated with ACE inhibitors remains the most frequently reported adverse effect leading to discontinuation, though its incidence varies among patient populations. Overall, Coversyl maintains a established position in cardiovascular therapy guidelines as an effective option for hypertension management and cardiovascular protection.